NEW YORK, Feb. 05, 2019 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (OTCQB: AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced it will report financial results for its fiscal third quarter ended December 31, 2018 after the market close on Wednesday, February 13, and will host a conference call and webcast at 4:30pm Eastern Time.
| Conference Call & Webcast | ||
| Wednesday, February 13th @ 4:30pm Eastern Time | ||
| Domestic: | 877-407-0784 | |
| International: | 201-689-8560 | |
| Passcode: | 13687310 | |
| Webcast: | http://public.viavid.com/index.php?id=133178 | |
| Replays, Available through February 27th: | ||
| Domestic: | 844-512-2921 | |
| International: | 412-317-6671 | |
| Conference ID: | 13687310 | |
About AIT Therapeutics Inc.
AIT Therapeutics Inc. is a clinical-stage medical device and biopharmaceutical company using nitric oxide (NO) to treat respiratory and other diseases. The Company is currently applying its therapeutic expertise to treat lower respiratory tract infections that are not effectively addressed with current standards of care, as well as pulmonary hypertension, in various settings. AIT Therapeutics is currently advancing its revolutionary NO Generator and Delivery System in clinical trials for the treatment of bronchiolitis and nontuberculous mycobacteria (NTM). For more information, visit www.AIT-Pharm.com.
CONTACT
Steven Lisi
Chief Executive Officer
AIT Therapeutics, Inc.
Steve@AIT-Pharm.com
Bob Yedid
LifeSci Advisors, LLC
Bob@LifeSciAdvisors.com
(646) 597 6989